Amgen and other biopharma leaders are embracing continuous manufacturing. Why? It's transforming how they produce life-saving medicines. Dive into a real-world case study: A hybrid continuous manufacturing process achieved: - 80% reduction in process media and buffer usage - 15x more product per batch - 45x higher productivity ...all without increasing costs or needing more space! The key? Smartly repurposing existing facilities and optimizing production times. The Impact: Lower costs for antibody therapeutics mean wider access for patients in need. Read the full study and learn how you can leverage these groundbreaking innovations below! https://hubs.ly/Q02MTsK50 #BiotechInnovation #PharmaManufacturing #HealthcareRevolution
Just - Evotec Biologics
Biotechnology Research
Seattle, WA 13,636 followers
Designing and applying innovative technologies to dramatically expand global access to biotherapeutics.
Über uns
Just – Evotec Biologics, wholly owned by Evotec SE, is a first-to-industry biologics platform that leverages AI/ML technologies and world-leading molecular design, cell line development, process intensification and continuous manufacturing strategies to advance biotherapeutics from discovery through clinical stages to commercial launch. The Just – Evotec Biologics team combines deep industry experience in the fields of data, protein, process, and manufacturing sciences including automation with highly integrated and flexible capabilities to break through the scientific and economic barriers associated with the development of protein therapeutics. Our focus is to accelerate and expand access to biotherapeutics through scientific and technological innovation for our proprietary projects and on behalf of our partners. Learn more at www.just-evotecbiologics.com
- Website
-
https://www.evotec.com/en/services/just-evotec-biologics
External link for Just - Evotec Biologics
- Industrie
- Biotechnology Research
- Größe des Unternehmens
- 501-1,000 employees
- Hauptsitz
- Seattle, WA
- Typ
- Öffentliches Unternehmen
- Gegründet
- 2014
- Spezialitäten
- Molecule Design/ Engineering, Process Development, Analytical Development, Formulation & Drug Product Development, Clinical Manufacturing, Discovery Services, Preclinical Manufacturing, cGMP Manufacturing, CDMO Services, Biosimilars, Antibody therapeutics, biologics manufacturing, cell line development, Biotherapeutics, Biologics, and Biomanufacturing
Standorte
-
Primäre
401 Terry Avenue North
Seattle, WA 98109, US
-
22857 NE Marketplace Drive
Redmond, WA 98053, US
-
195 route d‘Espagne
Toulouse, FR
Employees at Just - Evotec Biologics
Aktualisierungen
-
Read the August issue of our monthly newsletter for the latest updates and exciting developments in #continuousmanufacturing. Industry Round-Up: In a study published in the Journal of Pharmaceutical Sciences the authors discuss the advantages of decentralized manufacturing in small-scale production facilities. Read our key takeaways. News at Just - Evotec Biologics: Our new J.POD biologics manufacturing facility is set to open this September in Toulouse, France. Read the latest article discussing continuous biomanufacturing's arrival in Europe and our recent case study about how OncoResponse partnered with us to develop a continuous manufacturing process for their Phase I clinical trials. For full details, read our newsletter here- https://hubs.ly/Q02MSshb0
-
-
Step into the world of Evotec at CPhI Milan! Discover our tailored solutions and explore our API and drug product capabilities. Want to learn more about our API and drug product capabilities? Interested in our Just - Evotec Biologics development and #biomanufacturing services for #antibody & antibody-related therapeutics? Or perhaps our integrated continuous manufacturing platforms? And how about seeing our experts in action at our Verona site? Find all details here https://hubs.ly/Q02M2JWk0 - Don't wait to request a meeting or a site visit! #CPHI #drugdevelopment
-
-
Just – Evotec Biologics was thrilled to host a visit from the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to its Seattle and J.POD® Redmond, WA (US) facilities. This visit was part of the Manufacturing Optimization Program effort to enhance the U.S. Government’s rapid response capabilities for biologics medical counter measures in response to emergency situations. Just – Evotec Biologics will deliver an ultra-rapid, cost-efficient biotherapeutics manufacturing platform solution for the DODs Manufacturing Optimization Program. Learn more here- https://hubs.ly/Q02M2X0Y0 #biologics #biomanufacturing #Seattle
-
-
At our new GMP #biomanufacturing facility in Toulouse, #France, we use cleanroom pods that house our extremely intensified processes to manufacture biologics. Not only do these pods give us great flexibility, but we can also easily add new pods to increase our manufacturing capacity when needed. Our colleagues Philip Boehme and Nick Hutchinson discuss how it works. #biologics #continuousbiomanufacturing
-
Only 1 month to go before our J.POD® Toulouse facility launches! J.POD Toulouse, France (EU) features our #continuousbiomanufacturing platform to produce therapeutic #antibody #biotherapeutics. The facility hosts a full complement of process development services and GMP manufacturing all under one roof. Read about how continuous manufacturing arrives in Europe here- https://hubs.ly/Q02LStPV0 Contact Us: [email protected] #biomanufacturing #Toulouse #France
-
Learn how OncoResponse partnered with Just-Evotec Biologics to develop a #ContinuousManufacturing process that would supply their Phase 1 clinical trials. Just-Evotec Biologics provided: - J. MD Molecular Design Services - Our J.CHO High Expression System - Process Development and Scale-Up - Phase 1 Clinical Manufacturing Read the case study here: https://hubs.ly/Q02LpHFF0 #researchneverstops #Oncology #JustEvotecBiologics
-
-
Huge News! If you want to learn how to adopt continuous purification processes, we’re giving away some of our top tips! Download this amazing resource from Michelle Najera, Megan McClure, Shahbaz Gardezi and Beth Larimore here: https://hubs.ly/Q02LpKWt0 Learn how: 1. Process intensification solutions for monoclonal antibodies, Fc-fusion proteins and bispecific antibodies ease liquid handling pain points. 2. Our J.CHO High Expression System is delivering perfusion permeate titers of over 2 g/L/d over 25 days. 3. Continuous capture chromatography significantly enhances resin utilization 4. Two tank virus inactivation steps can be developed with bench-scale models Presented at 'Recovery of Biological Products XX' and titled “Turning the crank using a hybrid continuous purification platform” this is one not to miss. #continuousbiomanufacturing #justevotecbiologics #researchneverstops
-
-
It makes no sense to take an unoptimized #bioprocess into commercial manufacturing. If you went through IND with a rough-and-ready fed-batch process, we recommend you convert that to continuous before your BLA submission. When exactly should you do that? We encourage partners to do that as early in the clinical life cycle as they can. Here’s why: • Material generated for pivotal studies will be comparable with that from commercial manufacturing. • You’ll gain maximum experience and data for your regulatory filings from your new optimize continuous manufacturing process. • It will give you the benefits of continuous biomanufacturing in late-stage clinical supply, such as agility, flexibility and low cost of goods. To learn more, visit our website here- https://hubs.ly/Q02LpjwF0 Contact us: [email protected]
-
Evotec SE today announced its financial results and corporate updates for the first half-year of 2024. Dr Christian Wojczewski, Chief Executive Officer of Evotec, said, ““During my first few weeks at Evotec, I have been hugely impressed by the dedication of our world-class talent base, the quality of our leading-edge technology platforms, and the deep partnerships with top pharma and biotech. We are an R&D powerhouse. Our science, our partnerships, and our people are the core strengths on which we will continue to build." To read his full quote and to learn more, read the press release here- https://hubs.ly/Q02Ld6b-0 #ResearchNeverStops #TogetherForMedicinesThatMatter
-